Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Valk, Sarah J; Piechotta, Vanessa; Chai, Khai Li; Dorée, Carolyn; Monsef, Ina; Wood, Erica M.; Lamikanra, Abigail; Kimber, Catherine; McQuilten, Zoe; So‐Osman, Cynthia; Estcourt, Lise J; Skoetz, Nicole

doi:10.1002/14651858.cd013600

Cited by 162 publications

(205 citation statements)

References 80 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…However, this study was underpowered, terminating early with 103 out of the planned 200 patients owing to containment of COVID-19 in China. The only other evidence comes from isolated reports of the use of convalescent plasma in COVID-19, with a meta-analysis finding seven case series and one prospective single-arm study with a total of 32 participants ( 62 ). With small numbers, a lack of control groups, and a high risk of bias, no conclusions could be drawn about efficacy, and although serious adverse events were infrequent, they were not absent.…”

Section: Promoters Of the Innate Antiviral Responsementioning

confidence: 99%

Repurposing Existing Drugs for the Treatment of COVID-19

et al. 2020

View full text Add to dashboard Cite

The rapid global spread and significant mortality associated with the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection has spurred an urgent race to find effective treatments. Repurposing existing drugs is a particularly attractive approach as pharmacokinetic and safety data already exist; thus, development can leapfrog straight to clinical trials of efficacy, generating results far more quickly than de novo drug development. This review summarizes the state of play for the principle drugs identified as candidates to be repurposed for treating COVID-19 grouped by broad mechanism of action: antiviral, immune enhancing, and antiinflammatory or immunomodulatory. Patient selection, particularly with regard to disease stage, is likely to be key. To date, only dexamethasone and remdesivir have been shown to be effective, but several other promising candidates are in trials.

show abstract

Section: Promoters Of the Innate Antiviral Responsementioning

confidence: 99%

Repurposing Existing Drugs for the Treatment of COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A Cochrane review found much uncertainty as to whether convalescent plasma was effective in people admitted to hospital with covid‐19, because all eight studies, with a total of 32 patients, had a high risk of bias and the reporting quality was low. Lise Estcourt, head of NHS Blood and Transplant’s clinical trials unit, said that a trial of convalescent plasma for adults admitted to intensive care in England (REMAP-CAP)2 was ongoing and that researchers hoped to open a trial in all inpatients, in collaboration with the RECOVERY trial, for people of all ages.…”

Section: Convalescent Plasmamentioning

confidence: 99%

Seven days in medicine: 13-19 May 2020

2020

BMJ

View full text Add to dashboard Cite

“…Promising results (32 participants) and 48 ongoing trials were accumulated in a Cochrane analysis. 11 As defined below, cytokine storm (high serum levels of granulo-…”

Section: Introductionmentioning

confidence: 99%

The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect

Can

Coşkun

2020

Stem Cells Translational Medicine

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused coronavirus disease 2019 (COVID-19) pandemic has become a global health crisis with an extremely rapid progress resulting in thousands of patients who may develop acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) treatment. So far, no specific antiviral therapeutic agent has been demonstrated to be effective for COVID-19; therefore, the clinical management is largely supportive and depends on the patients' immune response leading to a cytokine storm followed by lung edema, dysfunction of air exchange, and ARDS, which could lead to multiorgan failure and death. Given that human mesenchymal stem cells (MSCs) from various tissue sources have revealed successful clinical outcomes in many immunocompromised disorders by inhibiting the overactivation of the immune system and promoting endogenous repair by improving the microenvironment, there is a growing demand for MSC infusions in patients with COVID-19-related ARDS in the ICU. In this review, we have documented the rationale and possible outcomes of compassionate use of MSCs, particularly in patients with SARS-CoV-2 infections, toward proving or disproving the efficacy of this approach in the near future. Many centers have registered and approved, and some already started, single-case or phase I/II trials primarily aiming to rescue their critical patients when no other therapeutic approach responds. On the other hand, it is also very important to mention that there is a good deal of concern about clinics offering unproven stem cell treatments for COVID-19. The reviewers and oversight bodies will be looking for a balanced but critical appraisal of current trials.

show abstract

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Cited by 162 publications

References 80 publications

Repurposing Existing Drugs for the Treatment of COVID-19

Repurposing Existing Drugs for the Treatment of COVID-19

Seven days in medicine: 13-19 May 2020

The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect

Contact Info

Product

Resources

About